{"id":546,"date":"2022-10-04T16:59:11","date_gmt":"2022-10-04T16:59:11","guid":{"rendered":"https:\/\/modafinil.pl\/sklep\/forskolin-forksolin-purity-%e2%89%a599-1000mg\/"},"modified":"2026-09-30T05:25:08","modified_gmt":"2026-09-30T05:25:08","slug":"forskolin-forksolin-purity-%e2%89%a599-1000mg","status":"publish","type":"product","link":"https:\/\/modafinil.pl\/en\/sklep\/forskolin-forksolin-purity-%e2%89%a599-1000mg\/","title":{"rendered":"Forskolin (CAS 66575-29-9) \u2014 laboratory reagent 1000 mg, purity \u2265 99%"},"content":{"rendered":"

[(3R,4aR,5S,6S,6aS,10S,10aR,10bS)-3-ethenyl-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-5,6,6a,8,9,10-hexahydro-2H-benzo[f]chromen-5-yl] acetate<\/strong>, more widely known as forskolin<\/strong>, crystalline powder, 1000 mg pack. Material intended exclusively for laboratory and analytical in vitro research<\/strong>. This product is not intended for human or animal consumption<\/strong>; it is not a medicinal product, food supplement, foodstuff or cosmetic.<\/p>\n

Three different entities that must not be confused<\/h2>\n

Forskolin requires the layers to be separated differently from most items in our catalogue \u2014 there is no simple \u201csubstance \u2014 registered medicine\u201d arrangement here. The same molecule is at once a constituent of over-the-counter preparations not regulated as pharmaceuticals and the starting point for the semi-synthesis of a compound that is<\/strong> a registered medicine \u2014 under a different name and a different CAS number. The table below separates these contexts:<\/p>\n\n\n\n\n\n\n\n
Separating the layers: substance \u2014 market preparation \u2014 reagent<\/caption>\n
Entity<\/th>\nWhat it is<\/th>\nStatus<\/th>\n<\/tr>\n<\/thead>\n
Chemical substance
forskolin, CAS 66575-29-9<\/th>\n		A chemical concept \u2014 a diterpenoid of defined structure, registered in databases (PubChem, ChEMBL). In itself it is neither a supplement, nor a medicine, nor a reagent; its status is conferred only by the form in which it has been manufactured and placed on the market.<\/td>\na chemical concept, not a product<\/td>\n<\/tr>\n
Extract \/ commercial preparation
standardised extract of Coleus forskohlii<\/em> root<\/th>\n		A preparation sold over the counter as an aid to weight loss, athletic performance or testosterone levels \u2014 without a pharmaceutical regime, without medicinal-product registration documentation, with a forskolin content set by the supplement manufacturer (most often declared as 10\u201320%).<\/td>\nthe human studies cited below concerned this form<\/strong> [13<\/a>][14<\/a>][15<\/a>]<\/td>\n<\/tr>\n
Chemical reagent
material offered here<\/th>\n		Material for laboratory and analytical work. It does not have, and cannot have, authorisation for use in humans or animals<\/strong> \u2014 it has no pharmaceutical form or medicinal-product documentation, nor is it a supplement preparation.<\/td>\nanalytics, chemistry, in vitro cell biochemistry<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

The consequence is unambiguous.<\/strong> The studies cited further on this page were conducted on finished commercial preparations<\/strong> (extract capsules given to volunteers in a clinical study setting), on isolated cells and membranes in vitro<\/strong>, or on laboratory animals<\/strong>. None of these studies was conducted using the analytical reagent<\/strong> described on this page, and none of their results transfers to the material offered.<\/p>\n

A separate matter: colforsin daropate.<\/strong> A chemical derivative of forskolin, obtained by attaching a group that improves water solubility (development code NKH477), is a registered medicine in Japan, administered intravenously in acute heart failure and in cardiac surgery [7<\/a>][9<\/a>]. It is a different chemical compound, with a separate CAS number<\/strong> \u2014 the registration of that medicine does not in any way concern forskolin as such or the reagent offered here.<\/p>\n

Reagent identification sheet<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Registry data and identifiers \u2014 forskolin<\/caption>\n
IUPAC systematic name (chromene nomenclature)<\/th>\n[(3R,4aR,5S,6S,6aS,10S,10aR,10bS)-3-ethenyl-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-5,6,6a,8,9,10-hexahydro-2H-benzo[f]chromen-5-yl] acetate<\/td>\n<\/tr>\n
Systematic name (labdane nomenclature)<\/th>\n7\u03b2-acetoxy-8,13-epoxy-1\u03b1,6\u03b2,9\u03b1-trihydroxylabd-14-en-11-one<\/td>\n<\/tr>\n
Common name<\/th>\nforskolin (forskolina), formerly coleonol<\/td>\n<\/tr>\n
CAS number<\/th>\n66575-29-9<\/td>\n<\/tr>\n
Molecular formula<\/th>\nC22<\/sub>H34<\/sub>O7<\/sub><\/td>\n<\/tr>\n
Molar mass<\/th>\n410.5 g\u00b7mol\u22121<\/sup><\/td>\n<\/tr>\n
Monoisotopic mass<\/th>\n410.2305 Da<\/td>\n<\/tr>\n
InChIKey<\/th>\nOHCQJHSOBUTRHG-KGGHGJDLSA-N<\/td>\n<\/tr>\n
SMILES (canonical)<\/th>\nCC(=O)OC1C(C2C(CCC(C2(C3(C1(OC(CC3=O)(C)C=C)C)O)C)O)(C)C)O<\/td>\n<\/tr>\n
PubChem CID<\/th>\n47936<\/a><\/td>\n<\/tr>\n
ChEMBL<\/th>\nCHEMBL3665034<\/a> \u2014 status: preclinical, clinical development phase 0<\/td>\n<\/tr>\n
Form<\/th>\ncrystalline powder<\/td>\n<\/tr>\n
Purity<\/th>\n\u2265 99%<\/td>\n<\/tr>\n
Intended use<\/th>\nresearch reagent \u2014 not for human or animal consumption<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Lineage of the molecule: from a root in Lucknow to a tool of cell biochemistry<\/h2>\n

The history of forskolin begins in a screening programme of medicinal plants, not in a synthetic laboratory. In the 1970s a team at the Central Drug Research Institute<\/strong> in Lucknow (India) examined extracts of Coleus forskohlii<\/em> root \u2014 a plant long used in the folk medicine of the Indian subcontinent \u2014 for blood-pressure-lowering activity in animals. The isolated compound was initially named coleonol<\/strong>; the first pharmacological report was published by Dubey and co-workers in 1981 [2<\/a>]. The name \u201cforskolin\u201d became established later \u2014 a summary of this path, from an Ayurvedic remedy to a research tool, was given in the 1985 review by Ammon and M\u00fcller [1<\/a>].<\/p>\n

Seamon\u2019s discovery: why chemists started looking for it in every laboratory<\/h3>\n

The breakthrough was not the isolation of the compound itself but the elucidation of its mechanism. In 1981 Kenneth Seamon and co-workers at the National Institutes of Health showed that forskolin activates adenylate cyclase directly<\/strong>, in cell membranes and cell cultures, bypassing G-protein-coupled receptors [3<\/a>] \u2014 an unusual result, as most activators of this enzyme known at the time acted indirectly, via a receptor. Two years later the same team published a structure\u2013activity relationship study of a series of derivatives, establishing which elements of the skeleton are essential for enzyme activation [4<\/a>]. Since then forskolin has been a standard biochemical tool for pharmacologically raising cAMP levels in experimental systems \u2014 an application distinct from extracts sold as market preparations.<\/p>\n

A derivative that reached the clinic \u2014 but not the same molecule<\/h3>\n

Natural forskolin is poorly soluble in water, which limited its usefulness as an intravenously administered medicine. The Japanese pharmaceutical industry developed a derivative with a solubility-enhancing group \u2014 development code NKH477<\/strong>, later named colforsin daropate<\/strong>. Hosono and co-workers described its cardiotonic properties in 1992 [7<\/a>], and subsequent papers compared its action with dobutamine, dopamine and isoproterenol [8<\/a>][9<\/a>]. In 2024 a paper appeared evaluating its repurposing in experimental oncology, in ovarian cancer cell lines [10<\/a>]. This is still a different chemical compound from the reagent offered here.<\/p>\n

Timeline<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Timeline: from isolation to modern research applications<\/caption>\n
1970s<\/th>\nscreening of Coleus forskohlii<\/em> extracts at the Central Drug Research Institute (Lucknow, India); isolation of the compound named coleonol<\/td>\n<\/tr>\n
1981<\/th>\nfirst pharmacological publication on coleonol [2<\/a>]; discovery by Seamon et al. of the mechanism of adenylate cyclase activation [3<\/a>]<\/td>\n<\/tr>\n
1983<\/th>\nstructure\u2013activity relationship study of forskolin derivatives [4<\/a>]; first report of intraocular pressure lowering in animals and man [11<\/a>]<\/td>\n<\/tr>\n
1985<\/th>\nreview \u201cfrom an Ayurvedic remedy to a modern agent\u201d [1<\/a>]<\/td>\n<\/tr>\n
1992\u20131994<\/th>\ndevelopment and study of the water-soluble derivative NKH477 \/ colforsin daropate [7<\/a>][8<\/a>]<\/td>\n<\/tr>\n
1993<\/th>\nclinical study of an inhaled form of colforsin in asthma, compared with fenoterol [16<\/a>]<\/td>\n<\/tr>\n
2002<\/th>\ncomparison of colforsin daropate with isoproterenol, dopamine and dobutamine in patients [9<\/a>]<\/td>\n<\/tr>\n
2005<\/th>\nclinical study of an oral preparation in overweight and obese men [13<\/a>]<\/td>\n<\/tr>\n
2006<\/th>\nthe derivative FSK88 described as an inducer of apoptosis in a gastric cancer cell line [18<\/a>]; clinical study of a preparation in the prevention of asthma attacks [14<\/a>]<\/td>\n<\/tr>\n
2010<\/th>\nHPLC-ELSD method for determining forskolin in multi-herbal weight-loss preparations [17<\/a>]; another clinical study in asthma [15<\/a>]<\/td>\n<\/tr>\n
2012<\/th>\nreview of the potential of forskolin in ophthalmology [12<\/a>]<\/td>\n<\/tr>\n
2014\u20132017<\/th>\nfull elucidation of the forskolin biosynthetic pathway in root cork cells of Coleus forskohlii<\/em> [5<\/a>][6<\/a>]<\/td>\n<\/tr>\n
2024<\/th>\nrepurposing of colforsin daropate tested in experimental oncology [10<\/a>]<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Research centres and context<\/h2>\n

The literature on forskolin falls into several clearly distinct strands, pursued at different centres and by different methods:<\/p>\n